SAUDI ARABIA
CERVICAL CANCER PROFILE

Morbidity and Mortality

Crude cervical cancer incidence per 100,000 women (2020): 2.4
Age-standardized cervical cancer incidence per 100,000 women (2020): 2.8
Cumulative risk of cervical cancer, ages 0-74 (2020): 0.3%
Cervical cancer deaths (2019): 160
Cervical cancer mortality-to-incidence ratio (2020): 0.5
Population-based cancer registry exists (2021): Yes

Primary Prevention

HPV vaccination programme coverage among girls (2020)

<table>
<thead>
<tr>
<th>Programme coverage*</th>
<th>Coverage by age 15 †</th>
</tr>
</thead>
<tbody>
<tr>
<td>no data</td>
<td>no data</td>
</tr>
</tbody>
</table>

HPV vaccination programme (2020):

HPV included in national vaccination programme: No
Scale of vaccination programme: -
Year of introduction: -
Primary target cohort: -

Related risk factors:

Tobacco use prevalence, women aged 15+ years (2020): 2%
Condom use at last high-risk sex (-): ND
HIV incidence per 1000, women aged 15+ years (2020): 0.02

Secondary Prevention

National screening programme for cervical cancer exists (2021): No
Primary screening test used (2021): -
Target age range of programme (2021): -
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): No
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): No

1 in 10 women have been screened for cervical cancer in the last 5 years

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): No

Cancer diagnosis and treatment services generally available (2021):

| Cancer centre or cancer department at tertiary level: | Yes |
| Pathology services (laboratories): | Yes |
| Cancer surgery: | Yes |
| Chemotherapy: | Yes |
| Radiotherapy: | Yes |

Palliative care for patients with NCDs in the public health system generally available (2021):

| In primary health care facilities: | No |
| In community or home-based care: | Yes |

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

ND = data not available
* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.